



This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Imaging			
68Ga-based prostate- specific membrane antigen (PSMA; FOLH1; GCPII)-targeted imaging agents	A study in mice suggests that two gallium-based compounds could be useful for imaging prostate cancer. In mice bearing both PSMA-positive and PSMA-negative human prostate cancer cells, PET scanning demonstrated specific labeling of the positive tumors. Next steps include conducting toxicity studies and synthesizing the compounds according to GMP protocols.	U.S. patent application filed by The Johns Hopkins University; licensed by Principio Inc.	Banerjee, S.R. et al. J. Med. Chem.; published online June 22, 2010; doi:10.1021/jm100623e Contact: Martin G. Pomper, Johns Hopkins Medical Institutions, Baltimore, Md.
	SciBX 3(27); doi:10.1038/scibx.2010.843 Published online July 15, 2010		e-mail: mpomper@jhmi.edu